Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentTORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026.Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentProfound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentArticle contentFourth Quarter and Full Year 2025 Results Conference Call Details:Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentDate: Thursday, March 5, 2026Article contentTime: 4:30 p.m. ETArticle contentLive Call Registration: https://register-conf.media-server.com/register/BI9b6f3d29fd3749db83543442274147c2Article contentThe call will also be broadcast live and archived on the Company’s website in the Investors section here.Article contentAbout Profound Medical Corp.Article contentProfound is a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures.Article contentProfound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).Article contentArticle contentProfound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.Article contentFor further information, please contact:Article contentStephen KilmerInvestor Relationsskilmer@profoundmedical.comT: 647.872.4849Article contentArticle contentArticle contentArticle contentArticle contentArticle contentTrending Telus picks former CIBC CEO Victor Dodig to replace Entwistle at helm Telecom CRA charged taxpayer instalment interest before he received all his GIC income Taxes For some Canadian travellers in Cuba, getting home is not so easy Airlines Russia memo sees return to U.S. dollar system in pitch made for Trump Economy Posthaste: Why Canada's job market is in a lot worse shape than you think News Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Telus picks former CIBC CEO Victor Dodig to replace Entwistle at helm Telecom CRA charged taxpayer instalment interest before he received all his GIC income Taxes For some Canadian travellers in Cuba, getting home is not so easy Airlines Russia memo sees return to U.S. dollar system in pitch made for Trump Economy Posthaste: Why Canada's job market is in a lot worse shape than you think News